November 17, 2026 FDA approves giredestrant for breast cancer Median progression-free survival was 10 vs 5.5 months with giredestrant vs comparator therapy. MDSpire News
November 17, 2026 FDA approves new pertuzumab biosimilar Approved for metastatic and early-stage breast cancer, the biosimilar cannot launch in the US before Q3 2028. MDSpire News
November 17, 2026 Can PET help spare chemo in HER2-positive breast cancer? Five-year findings show favorable disease control among selected patients, while ctDNA may offer additional insight into recurrence risk. MDSpire News
October 27, 2026 Endometrial cancer drug cuts progression or death risk 41% FDA grants Priority Review following improved survival versus chemotherapy in phase 3 trial. MDSpire News
October 09, 2026 Medical debt linked to higher late-stage cancer rates Lung cancer showed the strongest absolute association, while prostate and breast cancer findings diverged from the broader pattern. MDSpire News
October 07, 2026 Clitoral reconstruction may preserve sexual function Nearly 90% of patients reported preserved clitoral sensation and the ability to achieve orgasm following reconstruction. MDSpire News
September 28, 2026 Trends in alcohol-linked cancer mortality Investigators examined 3 decades of US cancer mortality estimates across age, sex, region, and cancer type. MDSpire News
September 21, 2026 FDA approves combo for ESR1-mutated breast cancer In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone. MDSpire News
September 08, 2026 FDA approves serial liquid biopsy testing In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death. MDSpire News
September 03, 2026 AI poised to reshape care “This is really a unique time in our careers to see such a large change in technology." MDSpire News